RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN THE TREATMENT OF OBESITY: SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS OF RANDOMIZED CLINICAL TRIALS
INTERNATIONAL BLEST SCIENTIFIC · 09.06.2026
DOI: 10.65671/vhs6ed16 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift INTERNATIONAL BLEST SCIENTIFIC, online erschienen am 09.06.2026. Verfasst von Luiz Felippe Mendes Caquetti.
Abstract (Originalsprache)
Introduction
Obesity is a chronic multifactorial disease associated with significant metabolic, cardiovascular, and inflammatory complications. The development of next-generation incretin-based therapies has substantially advanced obesity pharmacotherapy, particularly tirzepatide, a dual GLP-1/GIP receptor agonist, and retatrutide, a triple GLP-1/GIP/glucagon receptor agonist.
Objective
To compare the metabolic efficacy and safety profile of tirzepatide and retatrutide in the treatment of obesity through a systematic review and indirect comparative analysis of randomized clinical trials.
Methods
A systematic literature review was conducted using PubMed/MEDLINE, Scopus, and Web of Science databases. Randomized clinical trials involving adults with obesity or overweight associated with comorbidities were included. Data regarding weight reduction and treatment safety were extracted and analyzed through narrative synthesis and indirect comparison across independent studies.
Results
Tirzepatide demonstrated mean body weight reductions of up to 20.9% after 72 weeks of treatment in the SURMOUNT-1 trial. Retatrutide achieved mean weight reductions of up to 24.2% after 48 weeks in a phase 2 clinical trial. Both therapies showed substantial efficacy in promoting weight loss and improving metabolic parameters. Adverse events were predominantly gastrointestinal, including nausea, vomiting, diarrhea, and constipation. The absence of direct comparative studies limits definitive conclusions regarding differences between treatments.
Conclusion
Current evidence indicates that tirzepatide and retatrutide are promising therapeutic strategies for obesity management. Although preliminary findings suggest potential advantages associated with triple agonism, confirmation of clinical superiority requires direct comparative trials and further evidence from advanced-phase clinical studies.
Zitieren
APA
Caquetti, L. F. M. (2026). RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN THE TREATMENT OF OBESITY: SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS OF RANDOMIZED CLINICAL TRIALS. INTERNATIONAL BLEST SCIENTIFIC. https://doi.org/10.65671/vhs6ed16
Vancouver
Caquetti LFM. RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN THE TREATMENT OF OBESITY: SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS OF RANDOMIZED CLINICAL TRIALS. INTERNATIONAL BLEST SCIENTIFIC. 2026. doi:10.65671/vhs6ed16
BibTeX
@article{Caquetti2026,
author = {Caquetti, Luiz Felippe Mendes},
title = {RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN THE TREATMENT OF OBESITY: SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS OF RANDOMIZED CLINICAL TRIALS},
journal = {INTERNATIONAL BLEST SCIENTIFIC},
year = {2026},
doi = {10.65671/vhs6ed16}
}
EUVIMED